Communiqués Foresee Pharmaceuticals Co., Ltd.

Actions

6576

TW0006576002

Recherche biotechnologique et médicale

Cours en clôture Taipei Exchange Autres places de cotation 24/07/2026			Varia. 5j.	Varia. 1 janv.
82,00 ^TWD	-1,20%		+2,63%	+1,74%

09/07	Foresee Pharmaceuticals Co., Ltd. annonce la nomination de Brian J. Groch au poste de Directeur Commercial, à compter du 1er juillet 2026	CI
08/06	Le mirivadelgat, activateur oral de l'ALDH2 de Foresee Pharmaceuticals, entre en phase d'essais cliniques pour la maladie de Parkinson via l'étude de plateforme de phase 2A SLEIPNIR	CI

Communiqués

12/08/24	Foresee Pharmaceuticals Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectable Products	AQ
02/04/24	Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of CPP	AQ
31/10/23	Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease	AQ
02/10/23	Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	AQ
02/10/23	Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications	AQ
28/06/23	Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing	AQ
22/06/23	Foresee Pharmaceuticals Presented Poster on MMP-12 inhibitor, FP-020, in Genetic Model of Sarcoidosis at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases	AQ
15/08/22	Foresee Pharmaceuticals : will attend the investor conference held by Cathay Securities Corporation	PU
10/08/22	Foresee Pharmaceuticals : The submission of an IND for FP-045 in patients with Fanconi anemia by TRPharm to the Ministry of Health of Turkey	PU
08/08/22	Foresee Pharmaceuticals : Typo Corrections to the Company’s 2021 Annual Report	PU
08/08/22	Foresee Pharmaceuticals : Change of Internal Audit Officer of Foresee	PU
08/08/22	Foresee Pharmaceuticals : Board of Directors resolved to approve the 2022Q2 consolidated financial report	PU
03/08/22	Foresee Pharmaceuticals : announces phase 2 results of FP-025 in patients with Covid-19 associated ARDS	PU
27/07/22	Foresee Pharmaceuticals : The Submission of CAMCEVI 42 mg Marketing Authorization Application by Accord Healthcare, Foresee's Licensing Partner, to the MHRA of the UK	PU
20/07/22	Foresee Pharmaceuticals : announces the submission of a phase 3 IND to US FDA for FP-001 42 mg in patients with central precocious puberty	PU
08/07/22	Foresee Pharmaceuticals : will attend the investor conference held by Cathay Securities Corporation	PU
29/06/22	Foresee Pharmaceuticals : 2022 Annual Shareholders' Meeting resolutions	PU
09/06/22	Foresee Pharmaceuticals : announces the submission of New Drug Application for CAMCEVI 42 mg to TFDA	PU
31/05/22	Foresee Pharmaceuticals : announces EMA approval of CAMCEVI 42 mg for the treatment of advanced prostate cancer	PU
18/04/22	Foresee Pharmaceuticals : will attend the 11th Taiwan CEO Week held by Taiwan Stock Exchange and QIC	PU
05/04/22	Foresee Pharmaceuticals : The submission of Marketing Authorization Application by Megapharm for CAMCEVI 42 mg to the Ministry of Health of Israel	PU
05/04/22	Foresee Pharmaceuticals : CAMCEVI 42 mg Injection Emulsion launched in the U.S. for the Treatment of Advanced Prostate Cancer	PU
24/03/22	Foresee Pharmaceuticals : received positive CHMP opinion for CAMCEVI 42 mg for the treatment of advanced prostate cancer	PU
24/03/22	Foresee Pharmaceuticals : Board of Directors resolved to hold 2022 Annual Shareholders' Meeting	PU
24/03/22	Foresee Pharmaceuticals : Board of Directors resolved to submit the proposed issuance of common shares via private placement to Annual Shareholders' Meeting for discussion	PU